| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.32▲ | 8.32▲ | 8.32▲ | 8.28▲ | 8.11▲ |
| MA10 | 8.27▲ | 8.27▲ | 8.27▲ | 8.38▲ | 7.51▲ |
| MA20 | 8.25▲ | 8.28▲ | 8.30▲ | 8.14▲ | 6.17▲ |
| MA50 | 8.29▲ | 8.16▲ | 8.22▲ | 7.42▲ | 7.29▲ |
| MA100 | 8.40▲ | 8.49▲ | 7.90▲ | 6.03▲ | 15.94▼ |
| MA200 | 8.71▼ | 7.39▲ | 6.65▲ | 6.96▲ | 29.13▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.020▲ | 0.015▲ | 0.012▲ | -0.054▼ | 0.460▲ |
| RSI | 58.492▲ | 56.909▲ | 56.574▲ | 56.514▲ | 58.159▲ |
| STOCH | 69.794 | 69.794 | 69.794 | 36.709 | 50.250 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -48.276 | -44.840 |
| CCI | 203.056▲ | 203.423▲ | 210.387▲ | 52.084 | 65.179 |
| MA | $APVO Price Crossed Below MA(26) | Set Alert |
|
Thursday, August 06, 2020 06:15 AM
Extends Cash Runway into Q3 2021The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May ...
|
|
Wednesday, August 05, 2020 10:54 AM
SEATTLE, WA / ACCESSWIRE / July 21, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR ...
|
|
Sunday, August 02, 2020 08:17 AM
Before it's here, it's on the Bloomberg Terminal.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 07/08/20 | 8.20 | 8.55 | 8.20 | 8.55 | 59,866 |
| 06/08/20 | 8.40 | 8.50 | 8.06 | 8.12 | 135,015 |
| 05/08/20 | 8.44 | 8.44 | 8.03 | 8.28 | 57,910 |
| 04/08/20 | 8.21 | 8.40 | 8.01 | 8.35 | 82,026 |
| 03/08/20 | 8.38 | 8.44 | 8.07 | 8.09 | 134,600 |
| 31/07/20 | 8.56 | 8.71 | 8.20 | 8.40 | 128,463 |
| 30/07/20 | 8.36 | 8.98 | 8.25 | 8.57 | 156,200 |
| 29/07/20 | 8.40 | 8.51 | 8.05 | 8.34 | 116,145 |
| 28/07/20 | 8.60 | 8.8153 | 8.36 | 8.51 | 139,996 |
| 27/07/20 | 8.20 | 8.56 | 8.1263 | 8.56 | 170,023 |
|
|
||||
|
|
||||
|
|